RDInvesting Provides Investors with Free In-Depth Equity Reports on BSX, LGND, OPXA and RNN

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Boston Scientific Corporation (NYSE:BSX - News) shares increased 0.16 percent to close at $12.84 a share Monday. The stock traded between $12.69 and $13.14 on volume of 11.36 million shares traded. Analysts at Bernstein have recently upgraded the company's rating to "outperform" from "market perform". Shares of Boston Scientific have gained approximately 7.0 percent year-to-date.

Find out more about Boston Scientific including full access to the free equity report at:
www.RDInvesting.com/BSX

Ligand Pharmaceuticals Inc. (NASDAQ:LGND - News) shares declined 2.84 percent to close at $70.07 a share Monday. The stock traded between $66.68 and $72.82 on volume of 573,816 shares traded. Analysts at Brinson Patrick Securities have recently initiated coverage on the company with an "outperform" rating and a price target of $98.00. Shares of Ligand Pharmaceuticals have gained approximately 33.0 percent year-to-date.

Find out more about Ligand Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/LGND

Opexa Therapeutics Inc. (NASDAQ:OPXA - News) shares declined 2.02 percent to close at $1.94 a share Monday. The stock traded between $1.87 and $2.13 on volume of 988,784 shares traded. Analysts at Brinson Patrick Securities have recently initiated coverage on the company with a "buy" rating and a price target of $6.00. Shares of Opexa Therapeutics have gained approximately 6.0 percent year-to-date.

Find out more about Opexa Therapeutics including full access to the free equity report at:
www.RDInvesting.com/OPXA

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN - News) shares declined 0.77 percent to close at $1.29 a share Monday. The stock traded between $1.18 and $1.33 on volume of 6.75 million shares traded. Analysts at Brinson Patrick Securities have recently initiated coverage on the company with an "outperform" rating and a price target of $3.00. Shares of Rexahn Pharmaceuticals have gained approximately 150.0 percent year-to-date.

Find out more about Rexahn Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/RNN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com